Trial Profile
A retrospective study to evaluate the efficacy in patients with metastatic renal carcinoma treated with Axitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 27 Feb 2017 New trial record